Bexorg has now raised a total of $42.5 million since it spun out of Yale University research in 2021.
New Haven-based brain disease research startup Bexorg has announced it has raised $23 million in a Series A financing round.
The investment was led by Engine Ventures with participation from new backers Connecticut Innovations and E1 Ventures. Existing investors Amplify Partners and Starbloom Capital also participated.
Bexorg has now raised a total of $42.5 million since it spun out of Yale University research in 2021.
The company has
developed a technology platform that uses donated human brains, restoring specific molecular activities so that it can test potential drug candidates to treat degenerative diseases like Alzheimer's and Parkinson's.
“The support from this group of leading investors validates that Bexorg has established a new category of AI-enabled, whole human-brain infrastructure for drug discovery that identifies novel targets and biomarkers, unlocking new biology and opportunities in… drug development,” said Zvonimir Vrselja, CEO and co-founder of Bexorg.
Proceeds from the financing will be used to expand and improve the company’s AI engine, which is trained on data from the brain experiments, and to advance drug discovery and development programs through partners and in-licensed assets.
Ann DeWitt, general partner at Engine Ventures, and David Beyer, partner at Amplify Partners, will join the company’s board of directors.
